This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Zika Vaccine Program (Vaxart)
Drug Names(s): Zika Vaccine Program
Vaxart's Zika Vaccine Program is an oral vaccine for the treatment of Zika virus. Vaxart vaccines are administered using room temperature-stable tablets that can be stored and shipped without refrigeration, are easy to administer and reduce medical waste. The foundation of Vaxart’s platform is a non-replicating adenovirus type 5 vector (Ad5). Circumventing pre-existing immunity is especially important for Ad5-based vaccines because a majority of the human population has circulating antibodies against adenovirus, with a significant proportion having neutralizing antibodies. Vaxart addresses this problem by delivering the Ad5-vectored vaccine via tablet directly to the gut, an organ that doesn’t induce the same sort of anti-vector immunity, thus avoiding any neutralization by blood- or muscle tissue-based immune cells.
This approach requires the use of an adjuvant, as protein vaccines are generally not effective in the gut. Vaxart has developed a patented adjuvant that works through a toll-like receptor (TLR). TLRs have been applied in vaccines and are well-accepted as effective immune stimulators. Vaxart uses a TLR known to be fully effective in the gastrointestinal tract and has “coupled” the adjuvant to the target antigen. The end result is a demonstrable immune response when administered orally.
Zika Vaccine Program (Vaxart) News
Pink Sheet FDA Performance Tracker: CBER Approvals
Additional information available to subscribers only: